August 28th 2023
With an increased incidence of this sexually transmitted infection, a review of an older antibiotic for treatment has shown some clinical benefits in other countries.
July 31st 2023
The vaccine has been approved since late 2019 for adults age 18 and older.
July 26th 2023
The phase 1/2 trial evaluating EBT-101 dosed its first patient in September 2022.
The update refreshes the organization's 2022 guidance on HIV, viral hepatitis, and STI prevention, diagnosis, treatment, and care for key populations, focusing on people in prisons and other closed settings.
April 7th 2023
When taken within 3 days, doxycycline given post-exposure (doxy-PEP) decreased the incidence rates of syphilis, gonorrhea, and chlamydia significantly.
CRISPR Technique Identifies New Genes Affecting HIV Infection
Using CRISPR technology, investigators were able to “knock out” primary human CD4+ T cells, identifying new genes essential to HIV viral replication.
Computerized Cognitive Training Benefits HIV Patients
A meta-analysis showed that computerized cognitive training programs produced significant improvements in 6 cognitive and daily function domains among adults living with HIV.
HIV Virulence Stronger in Heterosexual Men
The study authors wrote that selection bias at transmission can shape HIV disease severity and tolerance in different groups.
FDA Approves Triumeq, ViiV Healthcare's Daily Treatment for Children Living With HIV
Today, the FDA approved the abacavir, dolutegravir, and lamivudine single tablet formulation Triumeq, a once-daily HIV treatment for children.
HIV Treatment Cabenuva Now Available for Adolescents 12 and Older
Today, the FDA approved the long-acting HIV treatment Cabenuva (cabotegravir and rilpivirine dually administered) for virologically suppressed adolescents 12 years and older.
Label Update for Cabotegravir and Rilpivirine Long-Acting HIV Treatment
With FDA Approval, the oral lead-in for the cabotegravir and rilpivirine long-acting HIV treatment (Cabenuva) is now optional. Clinical trial data showed similar safety and efficacy profiles for initiating the therapy with or without the oral lead-in.
“Ramp Up the Resources”: Increased Effort and Funding Needed to End HIV
Congress’s spending bill allocated drastically less funding for HIV testing, prevention, and treatment than previously promised. Carl Schmid, executive director of the HIV+Hepatitis Policy Institute, explains why it is so vital to continue the fight against HIV.
Kidney Impairment Risk Low for Oral PrEP Users
The study authors wrote that few people who initiate tenofovir disoproxil fumarate-based oral PrEP rarely experience clinically significant kidney impairment.
Readmission, Mortality are Post-Discharge Risks for HIV Patients
The study authors suggest further research and investment to identify areas of support for individuals at the highest risk of poor outcomes.
National Institutes of Health Launches Trial of 3 mRNA HIV Vaccines
With 3 vaccine candidates, the National Institutes of Health (NIH) is launching one of the first trials to examine the safety and efficacy of mRNA technology in HIV vaccination.
Impact of PEPFAR on HIV Testing and ART Initiation
This findings present an opportunity for countries to critically review testing approaches to develop specific targeted HIV testing.
Mean Monthly Out of Pocket PrEP Costs Drop between 2020 and 2021
The Affordable Care Act can remove financial barriers and increase access to PrEP, the study authors said.
FDA Issues CRL to Gilead for its Lenacapavir Due to Vial Compatibility Issues
The federal agency cited chemistry manufacturing and controls issues with vials.
FDA Authorizes First Condom for Anal Intercourse
The FDA approved the One Male Condom as the first condom approved and proven to protect against STIs and HIV during anal sex.
Optimizing ART for Patients With a History of Treatment Failure and Resistance
A review of treatment modalities for this patient population.
How Birthplace Affects the Care of Hispanic/Latino People Living With HIV
Hispanic/Latino people face disproportionately high HIV incidence, but one CROI 2022 study found those not born in the US are more likely to have stage 3 HIV (AIDS) diagnoses.
Pre-Exposure Prophylaxis and Antiretroviral Therapy Set UK on Track to Eliminate HIV
Due to policies rolling out HIV pre-exposure prophylaxis (PrEP) and commencing antiretroviral therapy at diagnosis, the UK is on track to eliminate new HIV infections among gay and bisexual men in approximately 25 years.
PLWH, Aging and the Effects of COVID-19 Outcomes
For people living with HIV (PLWH) an accelerated aging process may affect the severity of their disease.
STI and HIV Incidence Among German Test-Site Visitors
A study found 5% of German test-site visitors had a sexually transmitted infection. STI rates, including HIV incidence, were highest among men who have sex with men.
Utilizing Cord Blood for Treatment, A Woman is Considered Cured of HIV
This patient is the first mixed race woman to experience HIV-1 remission, and potentially opens up the door to others being treated with a novel treatment.
Black Americans Living With HIV Less Likely to Achieve Viral Suppression
Black patients enrolled in an LA Medical Care Coordination program were less likely to achieve viral suppression than HIV-positive people of other races.
Lifetime Risk of HIV Diagnosis in the US, Broken Down Demographically
Though HIV diagnoses have declined overall, new infections still disproportionately occur in certain racial, ethic, gender, and geographic populations.
Why Women Discontinue PrEP More Frequently Than Men
Investigators found a couple of different factors for this phenomenon.
Functional Impairment in People Living With HIV: A Global Study
In a global cohort, more than 1 in 3 people living with HIV reported functional impairments. Functional impairment was more common among HIV-positive people who were older, Black, or female.
Efficacy of COVID-19 Vaccination Among People Living With HIV in Taiwan
In a study of people living with HIV in Taiwan, COVID-19 vaccination was highly effective when implemented alongside non-pharmaceutical interventions.
Can Those Who Have HCV Benefit from PrEP?
Investigators looked to see if this population might be candidates for this form of HIV prevention.
HIV PrEP Awareness Increases Significantly, but Usage Still Lagging
One study presented at CROI 2022 found that HIV PrEP awareness increased among Latinx/Hispanic men who have sex with men, but usage has remained relatively stable for several years.
How Different Phases of the Pandemic Influenced Behavior, HIV Testing, and PrEP Starts
Boston’s Fenway Health looked at testing and prevention trends during 3 phases of the COVID-19 pandemic.
How to Price Injectable PrEP to Compete with Generic Oral PrEP
Investigators modeled what a long-acting injectable HIV prevention medication would have to cost in order for it to be justified when compared to generic, oral PrEP for HIV patients and transmission prevention.
New, Highly Virulent HIV Variant Found in the Netherlands
The VB variant likely originated in the late 1990s, and if left untreated, is more transmissible and deadly than prior HIV strains.
2 Clarke Drive Cranbury, NJ 08512